Large-Scale Pharmacovigilance Study Reveals Distinct Infection Risk Profiles Among Immune Checkpoint Inhibitors
Key Insights
A comprehensive analysis of 18,068 infectious adverse events from the FDA Adverse Event Reporting System reveals significant heterogeneity in infection risks among different immune checkpoint inhibitors (search), with atezolizumab and cemiplimab showing markedly elevated risks compared to pembrolizumab.
The study identifies over 70% of infectious complications occurring within the first three months of treatment, with pembrolizumab demonstrating the shortest median onset time of 27 days compared to other agents.
Specific infection patterns emerge across ICI classes, with bacterial pneumonia (search) and Clostridioides difficile colitis (search) showing strong associations with therapy, while elderly patients and those with lung cancer (search) represent particularly vulnerable populations requiring enhanced monitoring.
A comprehensive pharmacovigilance analysis of immune checkpoint inhibitor (ICI) therapy has revealed significant heterogeneity in infectious adverse event (iAE) risks among different agents, with important implications for clinical monitoring and patient safety. The study, analyzing 18,068 infectious complications from 147,854 immune-related adverse event reports in the FDA Adverse Event Reporting System (FAERS), provides the most extensive real-world assessment of ICI-associated infections to date.
Agent-Specific Risk Profiles Emerge
The analysis identified substantial differences in infection risk among ICI classes, challenging the assumption of uniform safety profiles across these agents. Atezolizumab demonstrated a reporting odds ratio (ROR) of 1.45 (95% CI 1.38-1.52), while cemiplimab showed an ROR of 1.42 (95% CI 1.31-1.54), both significantly elevated compared to pembrolizumab's lower risk profile (ROR 0.82, 95% CI 0.80-0.84).
The heterogeneity extends to specific infection types, with encephalitis (search) showing particularly strong associations with certain agents. Atezolizumab exhibited the highest signal for encephalitis among monotherapies (ROR 30.96), while combination therapy with nivolumab plus ipilimumab demonstrated markedly elevated encephalitis risk (ROR 17.72). These findings suggest clinically meaningful differences in safety profiles that may reflect distinct pharmacological properties, including variations in Fc-gamma receptor binding affinity that differentially modulate immune cell functions.
Temporal Patterns Guide Monitoring Strategies
Time-to-onset analysis revealed critical insights for clinical surveillance, with more than 70% of ICI-related infections occurring within the first three months of treatment initiation. The median onset time across all agents was 43 days (interquartile range 13-108 days), but significant agent-specific variations emerged.
Pembrolizumab demonstrated the shortest median onset time of 27 days (IQR 6-83), statistically significantly shorter than other regimens. In contrast, nivolumab showed the longest median onset time of 52 days (IQR 14-122), suggesting different immunological dynamics among agents. These distinct timelines indicate that while a general three-month monitoring period is applicable, peak risk periods may vary by specific agent.
Pathogen-Specific Associations Identified
The analysis revealed distinct patterns of pathogen-specific infections that provide insights into underlying mechanisms. Bacterial infections, particularly pneumonia bacterial (ROR 7.49) and Clostridioides difficile colitis (search) (ROR 2.11), showed significant associations with ICI therapy. Among fungal infections, Pneumocystis jirovecii pneumonia (search) demonstrated the strongest signal (ROR 3.78).
Viral infections presented complex patterns, with coronavirus pneumonia showing highly elevated signals (ROR 13.26), while COVID-19 and herpes zoster were frequently reported but with RORs below 1. The study also identified exceptionally high signals for rare events such as adrenalitis (ROR 187.80) and enterocolitis infectious (ROR 10.91).
A critical finding was the high proportion (71.55%) of infections with unspecified pathogens, highlighting significant diagnostic challenges in clinical practice and emphasizing the need for improved diagnostic strategies, including advanced molecular techniques.
Vulnerable Patient Populations
The analysis identified elderly patients (≥65 years) as a particularly vulnerable subgroup, with a pooled ROR of 1.10 (95% CI 1.04-1.16) across all ICIs. This age-related risk likely stems from immunosenescence impairing pathogen control, combined with frequent corticosteroid use for managing immune-related adverse events.
Lung cancer (search) emerged as the predominant indication associated with infectious complications (44.19% of cases), followed by melanoma (search) (21.61%). This pattern reflects both clinical prescribing trends and biological susceptibility, as lung cancer patients often have compromised respiratory immunity and frequent corticosteroid exposure.
Clinical Outcomes and Mortality
The study documented substantial clinical impact, with hospitalizations representing the most frequent serious outcome (36.50% of cases) and death or life-threatening events occurring in 21.05% of cases. Among anti-PD-1 (search) agents, nivolumab was associated with the highest hospitalization rate (68.74%), while avelumab showed notably high mortality rates (32.00%) among anti-PD-L1 (search) agents.
Combination therapies demonstrated particularly concerning outcomes, with nivolumab plus ipilimumab associated with substantially higher hospitalization rates (79.00%) compared to most monotherapies, consistent with known toxicity synergism in combination regimens.
Mechanistic Insights and Clinical Implications
The increased infection risk associated with ICIs operates through two interconnected pathways. First, checkpoint blockade directly disrupts immune homeostasis, potentially weakening control of opportunistic pathogens. Second, immunosuppressive treatments needed to manage immune-related adverse events create additional vulnerability to infections.
The findings support a risk-stratified approach to infection prevention and management. For higher-risk agents such as atezolizumab and cemiplimab, and combination therapies like nivolumab plus ipilimumab, intensified vigilance is warranted. The observation that over 70% of infections occur within the first 90 days establishes this as a critical monitoring window.
Study Limitations and Future Directions
While providing valuable insights, the analysis has inherent limitations as a spontaneous reporting system, including underreporting, selection bias, and variable data quality. The observational nature precludes causal inference, and confounding by comorbidities or concomitant medications remains possible.
Future research should focus on validating these signals through multicenter prospective studies, establishing animal models to confirm causal relationships, and developing improved diagnostic strategies for early detection of ICI-associated infections.
Clinical Practice Implications
These findings advocate for personalized monitoring strategies that align surveillance intensity with agent-specific risk periods. Enhanced vigilance is particularly important for older patients, those with lung cancer (search), and individuals receiving corticosteroids for immune-related adverse events. The strong signals for specific opportunistic infections support consideration of targeted prophylactic measures in high-risk scenarios.
As ICIs expand into earlier disease settings, addressing these infectious complications will be pivotal to optimizing patient outcomes while preserving the substantial therapeutic benefits of checkpoint inhibition in cancer treatment.